General Compounding

1. Effect of two work practice changes on the microbial contamination rates of pharmacy-compounded sterile preparations Trissel LA, Gentempo JA, Saenz LM et al.
2. Does your pharmacy have a compounding isolator? Labella CJ
3. Effect of additive selection on calculated aluminum content of parenteral nutrient solutions. Smith BS, Kothari H, Hayes BD, et al.
4. Potential for airborne contamination in turbulent- and unidirectional-airflow compounding aseptic isolators. Peters GF, McKeon MR, Weiss WT.
5. Impact of United States Pharmacopeia chapter 797: Results of a national survey. Candy TA, Schneider PJ, Pedersen CA.
6. Exenatide. Bray GM.
7. Medication safety infrastructure in critical-access hospitals in Florida. Winterstein AG, Hartzema AG, Johns TE, et al.
8. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Nahata MC, Morosco RS, Brady MT.
9. Physicochemical stability of highly concentrated total nutrient admixtures for fluid-restricted patients. Driscoll DF, Silvestri AP, Nehne J, et al.
10. Accuracy of parenteral nutrition solutions compounded with automated systems and by hand. Crill CM, Hak EB, Helms RA.
11. I.V. admixture contamination rates: Traditional practice site versus a class 1000 cleanroom. Thomas M, Sanborn MD, Couldry R.
12. Stability of roxatidine acetate in parenteral nutrient solutions containing different amino acid formulations. Oh J, Gwak H, Moon H, et al.
13. Calculating aluminum content in total parenteral nutrition admixtures. Driscoll M, Driscoll DF.
14. Hazard of compounded anesthetic gel Perrin JH.
15. Blueprint for implementing USP Chapter 797 for compounding sterile preparations. Kastango ES.
16. Physical compatibility of neonatal total parenteral nutrient admixtures containing organic calcium and inorganic phosphate salts. Parikh MJ, Dumas G, Silvestri A, et al.
17. Using a medium-fill simulation to evaluate the microbial contamination rate for USP medium-risk-level compounding Trissel LA, Gentempo JA, Anderson RW, et al.
18. USP chapter 797: Establishing a practice standard for compounding sterile preparations in pharmacy [PDF]. Kastango ES, Bradshaw BD.
19. National survey of quality assurance activities for pharmacy-compounded sterile preparations. Morris AM, Schneider PJ, Pedersen CA, et al.
20. Enterobacter cloacae bloodstream infections in pediatric patients traced to a hospital pharmacy [PDF]. Selenic D, Dodson DR, Jensen B, et al.
21. Using medium-fill simulation to establish a benchmark microbiological contamination rate for low-risk-level compounding [PDF]. Trissel LA, Ogundele AB, Ingram DS, et al.
22. Understanding the critical components of a successful cleanroom and barrier isolator project [PDF]. Rahe H.
23. ASHP national survey of pharmacy practice in hospital settings: Dispensing and administration–2002 [PDF]. Pedersen CA, Schneider PJ, Scheckelhoff DJ.
24. Compounding our problems–again [PDF]. Trissel LA.
25. Sterile compounding in hospital pharmacies [PDF]. [editorial] Talley CR. 
26. Upgrading quality assurance for pharmacy-prepared sterile products [PDF]. Zellmer WA.
27. ASHP invitational conference on quality assurance for pharmacy-prepared sterile products [PDF].
28. New JCAHO medication management standards for 2004 [PDF]. Rich DS.
29. Compatibility of argatroban with selected cardiovascular agents [PDF]. Honisko ME, Fink JM, Militello MA, et al.

Hazardous Sterile Preparations

1. Permeability of 13 different gloves to 13 cytotoxic agents under controlled dynamic conditions. Wallemacq PE, Capron A, Vanbinst R, et al.
2. Demand clean vials. Power LA.
3. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies. Connor TH, Sessink PJM, Harrison BR, et al.
4. Environmental exposure of health care workers to category D and X medications [PDF]. Timpe EM, Motl SE, Hogan ML.
5. Monitoring method for surface contamination caused by selected antineoplastic agents [PDF]. Larson RR, Khazaeli MB, Dillon HK.
6. Monitoring surface contamination by antineoplastic drugs using gas chromatography--mass spectrometry and voltammetry [PDF]. Schmaus G, Schierl R, Funck S.
7. Effectiveness of a closed-system device in containing surface contamination with cyclophosphamide and ifosfamide in an i.v. admixture area [PDF]. Connor TH, Anderson RW, Sessink PJ, et al.
8. Using a closed-system protective device to reduce personnel exposure to antineoplastic agents [PDF]. Wick C, Slawson MH, Jorgenson JA, et al.